A summary overview of the new, direct, target-specific oral anticoagulants
In the past 10 years or so, many alternatives to warfarin have been developed the first being the novel oral anticoagulants (NOAC) or better referred to as direct oral anticoagulants (DOAC) or target-specific oral anticoagulants (TSOAC). These drugs have some definite advantages and disadvantages th...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2016-08-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/4508 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849737534930681856 |
|---|---|
| author | G. L. Muntingh |
| author_facet | G. L. Muntingh |
| author_sort | G. L. Muntingh |
| collection | DOAJ |
| description | In the past 10 years or so, many alternatives to warfarin have been developed the first being the novel oral anticoagulants (NOAC) or better referred to as direct oral anticoagulants (DOAC) or target-specific oral anticoagulants (TSOAC). These drugs have some definite advantages and disadvantages that should be clear to physicians before prescribing any of them for patients. Many clinical trials have provided definitive information about the efficacy and safety of DOACs, yet many physicians remain sceptical about prescribing these drugs due to lack of answers to real world questions. The concerns are directed towards appropriate patient selection (the choice should be made according to age, renal function, compliance, cost, clinical condition, intake of other drugs), the mechanism of switching between agents, how these drugs affect routine laboratory tests and when monitoring is needed. Knowledge of other drugs that interact with the DOAC and management of severe bleeding will be reviewed and recommendations will be given to all of these concerns. |
| format | Article |
| id | doaj-art-bc46706e7b02461ebd810a723ca70cc8 |
| institution | DOAJ |
| issn | 2078-6190 2078-6204 |
| language | English |
| publishDate | 2016-08-01 |
| publisher | AOSIS |
| record_format | Article |
| series | South African Family Practice |
| spelling | doaj-art-bc46706e7b02461ebd810a723ca70cc82025-08-20T03:06:53ZengAOSISSouth African Family Practice2078-61902078-62042016-08-01584222510.4102/safp.v58i4.45083637A summary overview of the new, direct, target-specific oral anticoagulantsG. L. Muntingh0Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of PretoriaIn the past 10 years or so, many alternatives to warfarin have been developed the first being the novel oral anticoagulants (NOAC) or better referred to as direct oral anticoagulants (DOAC) or target-specific oral anticoagulants (TSOAC). These drugs have some definite advantages and disadvantages that should be clear to physicians before prescribing any of them for patients. Many clinical trials have provided definitive information about the efficacy and safety of DOACs, yet many physicians remain sceptical about prescribing these drugs due to lack of answers to real world questions. The concerns are directed towards appropriate patient selection (the choice should be made according to age, renal function, compliance, cost, clinical condition, intake of other drugs), the mechanism of switching between agents, how these drugs affect routine laboratory tests and when monitoring is needed. Knowledge of other drugs that interact with the DOAC and management of severe bleeding will be reviewed and recommendations will be given to all of these concerns.https://safpj.co.za/index.php/safpj/article/view/4508oral anticoagulantstarget-specificmechanismclinicalpharmacokinetics |
| spellingShingle | G. L. Muntingh A summary overview of the new, direct, target-specific oral anticoagulants South African Family Practice oral anticoagulants target-specific mechanism clinical pharmacokinetics |
| title | A summary overview of the new, direct, target-specific oral anticoagulants |
| title_full | A summary overview of the new, direct, target-specific oral anticoagulants |
| title_fullStr | A summary overview of the new, direct, target-specific oral anticoagulants |
| title_full_unstemmed | A summary overview of the new, direct, target-specific oral anticoagulants |
| title_short | A summary overview of the new, direct, target-specific oral anticoagulants |
| title_sort | summary overview of the new direct target specific oral anticoagulants |
| topic | oral anticoagulants target-specific mechanism clinical pharmacokinetics |
| url | https://safpj.co.za/index.php/safpj/article/view/4508 |
| work_keys_str_mv | AT glmuntingh asummaryoverviewofthenewdirecttargetspecificoralanticoagulants AT glmuntingh summaryoverviewofthenewdirecttargetspecificoralanticoagulants |